Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study
- 25 October 2019
- journal article
- research article
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 25, 8011-8018
Abstract
BACKGROUND:There is a growing recognition of sex-related disparities in atrial fibrillation (AF). However, limited data is available in Chinese AF patients. MATERIAL AND METHODS:We compared symptoms, quality of life (QoL), and treatment of AF accordi...Keywords
This publication has 35 references indexed in Scilit:
- Worldwide Epidemiology of Atrial FibrillationCirculation, 2014
- Women Versus Men with Chronic Atrial Fibrillation: Insights from the Standard Versus Atrial Fibrillation spEcific managemenT studY (SAFETY)PLOS ONE, 2013
- Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2011
- Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm AssociationEP Europace, 2007
- Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in EuropeJACC, 2007
- Gender-Related Differences in Atrial Fibrillation**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.JACC, 2005
- ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial FibrillationCirculation, 2004
- New-Onset Atrial FibrillationCirculation, 2001
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction: Safety Aspects and Effect on Atrial FibrillationCongestive Heart Failure, 2001
- Female gender as a risk factor for torsades de pointes associated with cardiovascular drugsJAMA, 1993